News

Press Release
RepliCel Signs Letter of Intention (Asset Purchase)
RepliCel announces a Letter of Intent for Asset Purchase AgreementVANCOUVER, BC, CANADA –March 18, 2024...
Press Release
Arbitration decision
RepliCel Life Sciences Announces Arbitration Decision VANCOUVER, BC – October 16, 2023 - RepliCel Life...
Press Release
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration ProceedingsVANCOUVER, BC, CANADA – September 13, 2023 –...
Press Release
David Kwok is appointed Chief Financial Officer
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is...
Press Release
RepliCel Adds an Additional Director, Jamie Mackay
 RepliCel Adds an Additional Director  RepliCel Life Sciences Strengthens Its Board of Directors as focus shifts...
AGM Announced for September 22, 2023
REPLICEL LIFE SCIENCES INC. Suite 900 – 570 Granville Street Vancouver, BC V6C 3P1 Telephone: (604) 248-8730 Fax:...
Press Release
RepliCel Announces Closing of Non-brokered Private Placement
RepliCel Announces Closing of Non-brokered Private PlacementNot for distribution to U.S. Newswire Services or for...
RepliCel Provides Corporate Update
Company Focus on Transformational Milestones Vancouver, BC, Canada – 28 November 2022 - RepliCel Life Sciences Inc. (TSXV:...
RepliCel Announces Material Patent Milestones in Key Markets
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key...
DermaPreciseTM Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
Independent Testing Performed by Innovacell Demonstrates the DermaPreciseTM Control Leads to Unparalleled Post-Injection Cell Survival and...
RepliCel’s Manufacturing Inspected by Japan’s PMDA
After over a year of pandemic-related delays, representatives of Japan’s PMDA, attended at the Company’s...
Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters...
Press Release
Replicel Announces Extension to Private Placement
VANCOUVER, BC – May 6, 2022 – Replicel Life Sciences Inc. (the “Company” or “Replicel”) announces...
Press Release
RepliCel Announces Non-brokered Private Placement
Not for distribution to U.S. Newswire Services or for dissemination in the United States.VANCOUVER, BC,...
Press Release,Product - RCI-02
RepliCel Announces Material Patent Milestones
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key...
Press Release
RepliCel Terminates License Agreement with Shiseido
VANCOUVER, BC, CANADA – 21 December 2021 – RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2)...
Press Release
RepliCel Closed Final Tranche of Strategic Investment Commitment
VANCOUVER, BC, CANADA – 21 December 2021 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel”...
Press Release
RepliCel Ships DermaPreciseTM Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection...
Press Release,Product - RCI-02
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
RepliCel’s CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearanceVANCOUVER, BC,...
Press Release
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
Trademark registrations kickoff pre-commercial planningVANCOUVER, BC, CANADA – 28 October 2021 – RepliCel Life Sciences...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.